You are here

Soliris

FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment

Reuters

Tue, 05/28/24 - 10:29 pm

AstraZeneca’s rare disease unit overcomes FDA snub to expand Ultomiris in NMOSD

Fierce Pharma

Mon, 03/25/24 - 10:31 pm

AZ's Alexion inks $125M deal to resolve investor lawsuit over Soliris sales tactics

Fierce Pharma

Thu, 09/14/23 - 11:00 pm

FDA blocks new use for AstraZeneca's Ultomiris

Pharmaphorum

Wed, 09/6/23 - 10:10 am

EHA 2023 – Astrazeneca keeps up its complement defense

EP Vantage

Fri, 06/9/23 - 10:01 am

Roche races to regulators after matching AstraZeneca's rare disease blockbuster in phase 3

Fierce Biotech

Tue, 02/7/23 - 11:04 am

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

Fierce Biotech

Fri, 12/16/22 - 10:47 am

ASH: Roche records phase 3 rare disease win ahead of Soliris showdown

Fierce Biotech

Mon, 12/12/22 - 10:29 am

Novartis, eyeing $3B market, beats AstraZeneca blood disorder blockbusters in phase 3

Fierce Biotech

Mon, 10/24/22 - 11:17 pm

clinical trials

Could This Biosimilar Drug Candidate Be a Winner for Amgen?

Motley Fool

Fri, 09/9/22 - 10:57 am

Roche and AstraZeneca settle years long patent battle over Ultomiris — report

Endpoints

Sun, 02/20/22 - 11:48 am

Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival

Endpoints

Fri, 02/4/22 - 11:11 am

clinical trials

myasthenia gravis

AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says

Fierce Pharma

Sun, 07/25/21 - 11:44 am

myasthenia gravis

Genentech posts long-term data on near-approval Soliris rival

Fierce Biotech

Fri, 05/22/20 - 10:46 am

Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report

Fierce Pharma

Tue, 04/7/20 - 07:10 pm

clinical trials

Apellis' blood disorder drug outdoes Alexion's Soliris in improving hemoglobin levels

Reuters

Tue, 01/7/20 - 10:55 am

Apellis Pharmaceuticals

Alexion Pharmaceuticals

Drugmakers rebranding around oncology, rare diseases could provide 2020 preview

Fierce Pharma

Thu, 12/19/19 - 11:32 pm

Alexion to Buy Achillion in $930M Marriage of Rare Disease Drug Firms

Xconomy

Wed, 10/16/19 - 12:48 pm

Alexion Pharmaceuticals

UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris

Fierce Biotech

Thu, 10/10/19 - 12:56 pm

Ra Pharmaceuticals

After rocky hep C path, Achillion finds surer footing with FDA breakthrough status

Endpoints

Wed, 09/25/19 - 11:32 pm

paroxysmal nocturnal hemoglobinuria

Pages